LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Sponsor
PETHEMA Foundation (Other)
Overall Status
Completed
CT.gov ID
NCT00526305
Collaborator
(none)
100
50
63
2
0

Study Details

Study Description

Brief Summary

Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.

Detailed Description

Remission Induction:
  • Vincristine (VCR): 1,5 mg/m2 i.v., days 1 and 8

  • Daunorubicin (DNR): 60 mg/m2 i.v., days 1 and 8.

  • Prednisone (PDN): 60 mg/m2/day, i.v. or p.o., days 1 to 14

  • L-asparaginase (L-ASA): 10.000 UI/m2, i.v.days 5-7 and 11-13

Results:
  1. Standard response: The induction treatment will be completed with the same drugs, changing L-ASA to ARA-C, during two more weeks

2 Slow response. Chemotherapy with mitoxantrone and high dose ARA-C

Intrathecal chemotherapy:

Treatment with mitoxantrone, ARA-C e hydrocortisone, days 1 and 22

CONSOLIDATION TREATMENT 1

Start in two weeks after last dose of induction chemotherapy:
  • Mercaptopurine (MP) 50 mg/m2, p.o., days 1-7, 28-35 and 56-63

  • Mitoxantrone (MTX): 3g/m2, i.v., in 24 hours, day 1, 28 and 56.

  • VM-26: 150 mg/m2 every 12 horas, i.v. (infusión 1 hora), días 14 y 42

  • ARA-C: 500 mg/m2 cada 12 hours, i.v., in 3 hours, days 14-15 and 42-43

  • Intrathecal treatment, days 28 and 56.

6.4. CONSOLIDATION TREATMENT 2

Start in a week after last dose of mercaptopurine of previous cycle

  • Dexamethasone (DXM):

  • 10 mg/m2 day, p.o. or i.v. days 1-14

  • 5 mg/m2 day, p.o. or i.v., days 15-21

  • Vincristine (VCR): 1,5 mg/m2 i.v., days 1 and 8 and 15

  • Daunorubicin (DNR): 30 mg/m2 i.v., days 1, 2, 8 and 9.

  • CFM 600 mg/m2 day, i.v., days 1 and 15

  • L-asparaginase (L-ASA): 10.000 UI/m2, i.v.or im , days 1-3 and 15-17

  • Intrathecal treatment days 1 and 15.

TRANSPLANTATION

Hematopoietic autologous transplantation with related donor, one or two months after last dose of consolidation treatment.

Hematopoietic autologous transplantation with unrelated donor, in patients younger than 45, and with PS 0-1

Hematopoietic autologous transplantation in patients without related donor and without unrelated donor after six months searching

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
Study Start Date :
Jan 1, 2000
Actual Primary Completion Date :
Apr 1, 2005
Actual Study Completion Date :
Apr 1, 2005

Outcome Measures

Primary Outcome Measures

  1. To evaluate the efficacy of treatment in order to response rate, relapse free survival and overall survival [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

ALL BCR/ABL+ patients Age < 65 years No previous treatment

Exclusion Criteria:
  1. Other LLA variability

  2. Previous history of coronary valvular, hypertensive cardiopathy illness

  3. Chronic hepatic illness

  4. Chronic respiratory insufficiency

  5. Renal insufficiency not caused by LLA

  6. Severe neurological problems not caused by LLA

  7. Severe affection of the performance status (grade 3-4 OMS gradation) not caused by LLA

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Central de Asturias Oviedo Asturias Spain
2 Hospital general de Castellón Castello Castellón Spain
3 Hospital de Navarra Pamplona Navarra Spain
4 Hospital Verge de la Cinta Tortosa Tarragona Spain
5 Complejo Hospitalario Universitario de Albacete Albacete Spain
6 Hospital General de Alicante Alicante Spain
7 Hospital Ntra. Sra. Sonsoles Avila Spain
8 Hospital de Badalona Germans Trias i Pujol Badalona Spain
9 Hospital Clínic Barcelona Spain
10 Hospital de Sant Pau Barcelona Spain
11 Hospital del Mar Barcelona Spain
12 Hospital vall d'Hebrón Barcelona Spain
13 Basurtuko Ospitalea Basurto Spain
14 Hospital de Cruces Bilbao Spain
15 Hospital de Jerez de la Frontera Jerez de La Frontera Spain
16 Complejo Hospitalario León Leon Spain
17 Hospital Arnau de Vilanova Lleida Spain
18 Complexo Hospitalario Xeral-Calde Lugo Spain
19 Clínica Puerta de Hierro Madrid Spain
20 Hospital 12 de Octubre Madrid Spain
21 Hospital Clínico San Carlos de Madrid Madrid Spain
22 Hospital de la Princesa Madrid Spain
23 Hospital General Universitario Gregorio Marañón, Madrid Madrid Spain
24 Hospital Universitario de la Princesa Madrid Spain
25 Althaia, Xarxa Asistencial de Manresa Manresa Spain
26 Hospital General Morales Meseguer Murcia Spain
27 Hospital General Universitario Morales Meseguer. Murcia Spain
28 Hospital Santa María del Rosell Murcia Spain
29 . Hospital Clínico Universitario Virgen de la Victoria Málaga Spain
30 H. Carlos Haya Málaga Spain
31 Complejo Asistencial Son Dureta Palma de Mallorca Spain
32 Hospital Son Llatzer Palma de Mallorca Spain
33 Clínica Universitaria de Navarra Pamplona Spain
34 Complejo Hospitalario de Pontevedra_Hospital Montecelo Pontevedra Spain
35 Corporació Sanitaria Parc Taulí Sabadell Spain
36 Hospital de Sagunto Sagunto Spain
37 Hospital Clínico Universitario de Salamanca Salamanca Spain
38 Complejo Hospitalario Universitario de Santiago Santiago de Compostela Spain
39 Hospital General de Segovia Segovia Spain
40 H.U. Virgen del Rocio Sevilla Spain
41 Hospital Universitario de Canarias Tenerife Spain
42 Hospital Clínico Universitario de Valencia Valencia Spain
43 Hospital Clínic Valencia Spain
44 Hospital dr. Peset Valencia Spain
45 Hospital General Universitario Valencia Spain
46 Hospital La Fe Valencia Spain
47 Hospital Clínico de Valladolid Valladolid Spain
48 Complejo Hospitalario Universitario de Vigo Vigo Spain
49 Hospital de Galdakao Vizcaya Spain
50 Hospital Clínico Lozano Blesa Zaragoza Spain

Sponsors and Collaborators

  • PETHEMA Foundation

Investigators

  • Study Chair: Ribera Josep Mª, Dr, Germans Trias i Pujol Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00526305
Other Study ID Numbers:
  • LAL-Ph-2000
First Posted:
Sep 10, 2007
Last Update Posted:
Jan 5, 2010
Last Verified:
Jan 1, 2010

Study Results

No Results Posted as of Jan 5, 2010